Recro Pharma Inc. Initiated its second phase-III clinical study in as many weeks for its lead new pain drug candidate.
Phase-III trials are typically the last step a company takes before seeking approval for an experimental therapy.
Recro (NASDAQ: REPH) of Malvern, Pa., is developing multiple non-opioid therapeutics for the treatment of pain.
Read the full story here.
For more business related news, visit PBJ.com.
Copyright bizjournal
